Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (302)	9/4/1999 3:23:00 PM
From: LLCF	Read Replies (2) \| Respond to of 666

<I believe that CLTR management was blindsided.> Which would make this one HELL of a buying opportunity... I've added down here based on many informative posts, thanks very much. Being a bio-neophyte I've got very little to add except a general comment that stuck out in my mind from one of the negative articles. That is the arguement that the FDA works along with the company during the 45 [60?] day period implying "give and take" and communication. If this is anything like my experience with various governmental agencies [not FDA], this sounds a bit exaggerated at best, and laughable at worst. Can anyone shed light on the reality of FDA-Company communications between filing and acceptance/rejection... and would large pharma get preferential treatment simply because they have lackies [whole departments?] to continue "bugging" these people for example? Again thanks to all on the CLTR thread for the great commentary on the ongoing CLTR saga... DAK